February 4, 2020



News
January 31, 2020
Navrogen Opens R&D Operations at Cheyney University
November 20, 2019
Navrogen Inc. and Lonza Sign Agreement to Use Lonza’S GS Gene Expression System® for Navrogen’s Anti-HIO Targeting Agents
October 1, 2019
Navrogen Enters into CRADA with the U.S. National Cancer Institute to Develop Agents to Overcome Tumor-Mediated Immunosuppression
September 17, 2019